June 17, 2016
Genetic Signatures Launches Analyte Specific Reagents in the US
- Further step towards full product suite commercialisation in the US
- Allows uptake of Genetic Signatures 3base™ technology in up to 11,000 CLIA certified laboratories in the US
- To be officially launched during the American Society of Microbiology conference on June 17, 2016
Sydney, Australia, 17 June, 2016: Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) will today launch a range of Analyte Specific Reagents (ASRs) in the United States. These ASR products utilise the company’s proprietary 3base™ technology and cover a range of pathogen targets. US Laboratories regulated by the Clinical Laboratory Improvement Act (CLIA) may purchase and use ASRs as building blocks to develop and validate proprietary tests for the diagnosis of infectious diseases. These laboratory-developed tests are commonly used in the US market and are offered in up to 11,000 CLIA certified laboratories1.
The ASR products will be officially launched at the American Society of Microbiology conference, Boston, June 17-20, 2016. Genetic Signatures will be exhibiting and showcasing their full product range to more than 10,000 attendees.
“We know that the market in the US seeks technologically superior products that may be used in laboratory-developed tests.” said Mr. Mike Aicher, President of Genetic Signatures US. “This is the next logical step for Genetic Signatures after FDA listing of our Clinical Concentrator Kit, which we completed in August of 2015.”
“This progressive step in our US market entry strategy brings our proprietary 3Base™ technology to the majority of hospital and commercial laboratories in the US,” said Genetic Signatures’ Chief Executive Officer, John Melki PhD. “We believe that our technologically superior ASRs will be well received by the American market.”
About Analyte Specific Reagents: The US Food and Drug Administration (FDA) defines Analyte Specific Reagents as “antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents, which through specific binding or chemical reactions with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens.” 21 CFR 864.4020
1http://www.acla.com/wp-content/uploads/sites/2/2014/09/Alan-Mertz-Written-Statement-for-21st-Century-Cures-Hearing-2014-09-09.pdf
April 28, 2016
Quarterly Cash Flow & Activities Report – GSS Amended Appendix 4C 31 March 2016
February 26, 2016
Half-Yearly Cash Flow and Activities Report – GSS Appendix 4D 31 December 2015
January 29, 2016
Quarterly Cash Flow & Activities Report – GSS Amended Appendix 4C 31 December 2015
November 6, 2015
University of California Los Angeles to Collaborate with Genetic Signatures on Transformative Molecular Platform Technology
Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced a collaboration with Dr. Scott Binder MD and his Microbiology team at the University of California, Los Angeles (UCLA) to analyze molecular testing methods for bacteria, viruses and parasites as compared to traditional testing in an effort to reduce the spread of infection in the US healthcare system.
October 30, 2015
Quarterly Cash Flow & Activities Report – GSS Appendix 4C 30 September 2015
October 20, 2015
GSS CEO Presentation at the 6th Annual Australian Microcap Investment Conference
- The largest conference in Australia focussed on emerging companies
- Presentations will be given by the CEOs of 20 of Australia’s leading microcaps
- Genetic Signatures to present its global growth strategy for the development and supply of world leading diagnostic solutions
Genetic Signatures (ASX: GSS) is pleased to release a copy of the presentation that Chief Executive Officer, John Melki, PhD., will deliver today at the 6th Annual Australian Microcap Investment Conference.
Dr Melki will present on Genetic Signatures’ technology, commercialisation progress, financial results, and track record. The presentation will also detail the Company’s global revenue growth strategy for the sale of world leading solutions for the rapidly growing infectious disease detection market.
Dr Melki said: “It is pleasing that Genetic Signatures is seen as one of Australia’s leading microcap investment opportunities. It is an exciting time for the Company and I am looking forward to sharing the news of our success to date and plans for future global expansion and growth.”
October 1, 2015
Resignation of Director
Genetic Signatures Limited announces the resignation of Mr Patrick Noland as a Non- executive Director of the company to take up his new position in the company as Executive Vice President, US Operations. On September 22, 2015 Genetic Signatures announced the appointment of Mr Patrick Noland to the full-time position of Executive Vice President of US Operations.
September 29, 2015
Change of registered office address
Genetic Signatures Limited (ASX: GSS) advises effective today the Company’s registered office details have changed to:
Level 12,
680 George Street, Sydney NSW 2000.
Ph: +61 2 8280 7100
September 28, 2015
Date of 2015 Annual General Meeting
Genetic Signatures Limited (ASX: GSS) advises that its 2015 Annual General Meeting will be held on Monday 9 November 2015.